Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Abstract Immunotherapy, especially anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) treatment has significantly improved the survival of non-small cell lung cancer (NSCLC) patients. However, the overall response rate remains unsatisfactory. Many factors affect the out...
Salvato in:
| Autori principali: | , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMC
2021-03-01
|
| Serie: | Experimental Hematology & Oncology |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1186/s40164-021-00211-8 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|